Ignite Creation Date:
2024-05-06 @ 12:32 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03789643
Status:
WITHDRAWN
Last Update Posted:
2019-05-03
First Post:
2018-12-26
Brief Title:
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
Sponsor:
Akros Pharma Inc
Organization:
Akros Pharma Inc
Study Overview
Official Title:
A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of JTT-251 Administered for 24 Weeks to Participants With Pulmonary Arterial Hypertension RELIEF-PAH
Status:
WITHDRAWN
Status Verified Date:
2019-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Corporate decision priority change
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RELIEF-PAH
Brief Summary:
Study to evaluate the efficacy safety tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension PAH
Detailed Description:
This is a study to evaluate the efficacy safety tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension PAH Participants completing this study RELIEF-PAH will be eligible to enroll in an open-label extension study RELIEF-PAH OLE to evaluate the long-term efficacy safety tolerability and pharmacokinetics of JTT-251 in participants with PAH
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None